display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
non squamous - mNSCLC - L1 - all populationnon squamous - mNSCLC - L1 - Wild Type (WT)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel IMpower-150 ... IMpower-150 ... IMpower-150 ...
atezolizumab plus carboplatin plus nab-paclitaxel IMpower-130 ... IMpower-130 ...
atezolizumab plus carboplatin plus paclitaxel IMpower-150 ...
atezolizumab plus pemetrexed and platin IMpower-132 ...
pembrolizumab based treatment
pembrolizumab and pemetrexed plus platin KEYNOTE-021
pembrolizumab plus SoC KEYNOTE-189

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons